Peptide therapeutics are short chains of amino acids (typically 2-50) that act as drugs, signaling molecules, and delivery vehicles. The field has been revolutionized by GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which have become the best-selling drug class in history for treating obesity and diabetes. Beyond metabolic medicine, peptides play a growing role in longevity science (MOTS-c, GHK-Cu, Epitalon), CRISPR delivery via cell-penetrating peptides, and peptide-based partial epigenetic reprogramming, making them a bridge between traditional pharmacology and genetic medicine.
Semaglutide, tirzepatide, and the next generation of weight loss peptides
MOTS-c, GHK-Cu, Epitalon, BPC-157, and their evidence base
Short peptides that shuttle CRISPR and other cargo across cell membranes
SPPS manufacturing and the supply chain powering the GLP-1 revolution
Ring-structured peptides with improved stability and drug-like properties
Contract manufacturers like Bachem and PolyPeptide scaling peptide production
In-depth analysis and expert-level coverage
A comprehensive, scientifically honest guide to BPC-157 — what the animal data actually shows, why zero human clinical trials have been completed, the legal gray zone in 2026, and what anyone considering this peptide needs to know.
Semaglutide and other GLP-1 receptor agonists are proving to be far more than weight-loss drugs. From cardiovascular protection and kidney disease to addiction, Alzheimer's, and sleep apnea, the expanding therapeutic reach of this peptide class is reshaping medicine.
From record-fast oral GLP-1 approvals and Medicare coverage to compounding crackdowns and RFK Jr.'s peptide reclassification push — a comprehensive look at every major FDA and US healthcare action on peptides in 2025-2026, which companies benefit, and what it means for patients and investors.
Amycretin is Novo Nordisk's investigational oral GLP-1 + amylin dual agonist. What the Phase 1 data showed and why oral delivery matters.
Antimicrobial peptides span ancient innate immunity and modern FDA-approved antibiotics like daptomycin and colistin—now central to the AMR drug-discovery revival.
Tirzepatide delivers 21% weight loss — at $1,000/month, forever. Could a single base-editing infusion ever replace the injection entirely?
Bimagrumab plus GLP-1 is the leading strategy to preserve muscle during obesity drug treatment. Inside Lilly's $1.9B Versanis acquisition.
BPC-157 is everywhere in biohacker circles. A rigorous 2026 review of what the peer-reviewed evidence actually shows about this gastric peptide.
CagriSema is Novo Nordisk's cagrilintide + semaglutide fixed-dose combo for obesity. REDEFINE-1 Phase 3 showed 22.7% weight loss — below internal expectations.
Calcitonin peptide therapy was once a frontline osteoporosis drug. A cancer signal, modest efficacy, and better rivals pushed it to the margins—but it still has clinical roles.
The cancer peptide vaccine field has been reborn around personalized neoantigens, mRNA delivery, and combinations with checkpoint inhibitors. Here's the 2026 state of play.
Cell penetrating peptides are quietly solving CRISPR's biggest problem — getting the scissors inside the cell. A deep evidence review.
CJC-1295 and ipamorelin are the most popular growth hormone peptide stack in biohacker circles. Here is what the evidence actually says.
Copper peptides for skin have stronger evidence than most cosmetic actives. Here is how GHK-Cu and AHK-Cu work, what trials show, and which products actually deliver them.
Cyclic peptides explained — how head-to-tail, stapled, and bicyclic designs engineer stability, affinity, and oral bioavailability beyond Lipinski's rule of five.
Danuglipron was Pfizer's flagship oral GLP-1 bet for obesity. A look at what it was, why it failed, and what the discontinuation means.
Epitalon is marketed as a telomerase-activating longevity peptide. A rigorous look at what the evidence actually shows — and what it doesn't.
GHK-Cu modulates thousands of genes toward a younger expression profile. What this copper peptide actually does — and what it doesn't.
How insulin analogs evolved from 1920s pancreas extracts into engineered peptides that anchor modern diabetes therapy and biotech.
Leuprolide and other GnRH analogs are peptides that paradoxically shut down sex hormone production — the backbone of androgen deprivation therapy.
The 2026 longevity stack combines senolytics, peptides, and partial reprogramming into one framework. See which interventions have clinical evidence and how they layer.
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA, acting as an exercise-mimetic hormone. A rigorous look at the longevity evidence.
Octreotide is the cyclic 8-amino-acid analog of somatostatin that revolutionized treatment of acromegaly, carcinoid syndrome, and neuroendocrine tumors.
Orforglipron is Eli Lilly's oral non-peptide GLP-1 agonist — a once-daily pill with no food or water restrictions, delivering ~15% weight loss in Phase 2.
Oxytocin peptide therapy spans labor induction, autism research, and social cognition trials—with a mixed evidence base and a landmark history in peptide chemistry.
Pitocin oxytocin medical use is the oldest peptide drug story in obstetrics—Nobel-winning chemistry, decades of safety data, and modern long-acting analogs.
Pemvidutide is Altimmune's balanced GLP-1/glucagon dual agonist peptide, posting 59% MASH resolution and 15.6% weight loss in Phase 2.
Peptides and CRISPR are converging on the same disease targets, sharing delivery infrastructure, and increasingly working together inside single therapeutic programs.
Why peptide drug delivery is hard — proteolysis, permeability, half-life — and how lipidation, SNAC, LNPs and microneedles are finally solving the bioavailability problem.
A rigorous review of peptide therapy side effects — from GLP-1 class risks to research-chemical contamination, immunogenicity, and gray-market hazards.
A rigorous look at the most common peptide stacks in longevity and biohacker communities — what they are, what evidence supports them, and what does not.
PT-141 (bremelanotide, brand name Vyleesi) is an FDA-approved melanocortin peptide that acts centrally on brain circuits to treat hypoactive sexual desire disorder.
Retatrutide is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors—delivering up to 24% weight loss in Phase 2 trials.
Selank and Semax are Russian nootropic peptides claimed to boost BDNF and reduce anxiety. We examine the evidence, mechanism, and regulatory reality.
A rigorous look at the semaglutide mechanism, tirzepatide's dual GLP-1/GIP agonism, and head-to-head trial data from SUSTAIN, STEP, SURPASS and SURMOUNT-5.
Solid phase peptide synthesis explained — Merrifield's Nobel-winning invention, Fmoc vs Boc chemistry, and why SPPS is the bottleneck behind the GLP-1 boom.
Survodutide (BI 456906) is a Phase 3 dual GLP-1/glucagon peptide agonist for MASH and obesity. Here is the mechanism, trial data, and pipeline positioning.
TB-500 is marketed as a synthetic thymosin beta-4 for tissue healing. The real story is more complicated, and the human evidence is thinner than advertised.
Teduglutide is the engineered GLP-2 peptide that lets short bowel syndrome patients absorb more nutrition and reduce reliance on IV feeding.
Teriparatide is the PTH 1-34 fragment that paradoxically builds bone instead of breaking it down — a landmark anabolic peptide for severe osteoporosis.
Tesamorelin is an FDA-approved GHRH analog for HIV lipodystrophy that gained longevity attention after the TRIIM trial reported epigenetic age reversal.
Thymosin alpha 1 (Zadaxin) is approved in 30+ countries but not the US. Here is the mechanism, hepatitis and COVID trial data, and FDA 503A status.
Yamanaka factors peptide delivery — why protein-based reprogramming with cell-penetrating peptides may be the safest path to clinical partial reprogramming for aging.
The ziconotide cone snail peptide (Prialt) is FDA-approved for severe chronic pain, blocks N-type calcium channels, and proves nature builds better drugs than chemists.
Accessible introductions for newcomers
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates the same metabolic pathways as exercise. Here's what the science says about the so-called 'exercise in a bottle.'
GHK-Cu is a naturally occurring copper peptide that declines with age and plays a role in wound healing, collagen synthesis, and gene expression. Here is what the science actually supports — and where the hype runs ahead of the evidence.
A head-to-head comparison of the three leading incretin-based therapies — semaglutide, tirzepatide, and retatrutide — covering mechanisms, weight loss data, side effects, cost, and who each one is best suited for.
Eli Lilly's retatrutide activates three metabolic receptors at once — GLP-1, GIP, and glucagon — producing up to 24.2% weight loss in Phase 2 trials. Here's how it works, how it compares to semaglutide and tirzepatide, and what to expect from Phase 3.
Novo Nordisk's oral Wegovy pill launched in January 2026, giving patients a needle-free path to GLP-1 weight loss. Here's how the 50 mg tablet stacks up against the weekly injection on efficacy, side effects, cost, and convenience.
GLP-1 alcohol addiction evidence review: does Ozempic reduce drinking? Covers Leggio's NIAAA research, 2024 Molecular Psychiatry trial, and mechanism.
GLP-1 and Alzheimer's: complete 2026 evidence review covering EVOKE trials, liraglutide ELAD data, and whether semaglutide slows cognitive decline.
GLP-1 and kidney disease: the FLOW trial showed semaglutide cut major kidney events 24% in diabetic CKD. Full trial breakdown and clinical implications.
GLP-1 muscle loss explained: how much lean mass you lose on Ozempic, what STEP DEXA data shows, and evidence-based mitigation strategies.
Complete evidence-based guide to GLP-1 side effects from Ozempic, Wegovy, and Mounjaro — incidence rates, dose escalation strategy, and rare risks.
How does Ozempic work? A clear 2026 guide to GLP-1 drugs, the four mechanisms behind semaglutide, and how it compares to Mounjaro and Zepbound.
How long does Ozempic take to work? Appetite drops within days, steady-state in 4–5 weeks, peak weight loss at week 68. Full evidence timeline.
A beginner's guide to natural peptides in the body: insulin, oxytocin, glucagon, vasopressin, glutathione and how they shape therapeutic peptides.
Ozempic face explained: what causes it, why rapid weight loss affects facial appearance, and prevention strategies backed by dermatology evidence.
What is a peptide bond? A clear beginner's guide to amino acids, condensation reactions, and how peptide bonds shape every protein in your body.
A science-based beginner's guide to peptides for longevity — Epitalon, GHK-Cu, BPC-157, MOTS-c — honest evidence and the regulatory reality.
Peptides vs proteins: a clear explanation of size, structure, synthesis, and why the distinction matters for drug design and biology.
A clear beginner's guide to what peptides are, how the body makes them, and why peptide therapeutics are transforming medicine in 2026.
What happens when you stop Ozempic? Roughly two-thirds of weight lost returns within a year. Full trial data and strategies to maintain loss.
Company analysis, trends, and investment insights
A 2026 investor guide to GLP-1 stocks: Novo Nordisk vs Eli Lilly, pipeline, market cap, risks, and the obesity drug challengers to watch.
The longevity peptide startups worth watching in 2026: BioAge, Rejuvenate Bio, Life Biosciences, Loyal, New Limit. Honest risks and realistic expectations.
Why peptide manufacturing became the GLP-1 bottleneck. A 2026 investor guide to Bachem, PolyPeptide, Lonza, and the peptide CDMO pick-and-shovel trade.
How to invest in the peptide therapeutics boom via ETFs and funds. Obesity-themed, broad biotech, and pharma mega-cap options compared for 2026.
Watch the four-mechanism action of GLP-1 peptide drugs — from injection to pancreas to stomach to brain. An interactive visual guide to the biggest peptide breakthrough in medicine.
Beginner · 3 minWatch the Merrifield solid-phase peptide synthesis cycle in action — from resin bead to finished peptide drug. Understand the chemistry that powers the GLP-1 revolution.
Intermediate · 4 minWatch a cell-penetrating peptide carry a CRISPR-Cas9 ribonucleoprotein across a cell membrane and into the nucleus. The flagship explainer tying peptides to gene editing.
Advanced · 4 minThe building block of peptides and proteins. There are 20 standard amino acids, each with a unique side chain. They link via peptide bonds to form peptide chains.
The fraction of an administered drug that reaches systemic circulation. Peptides historically have very low oral bioavailability due to gut proteases and poor membrane permeability — which is why most are injected.
Body Protection Compound 157 — a synthetic pentadecapeptide derived from a gastric protein. Popular in biohacker circles for claimed tissue-repair effects, but lacks human clinical trials, is banned by WADA (2022), and is restricted by FDA 503A compounding rules (2023). Not FDA-approved.
A short peptide (typically 5–30 amino acids, often cationic like poly-arginine or TAT) that can cross cell membranes and carry cargo such as proteins, nucleic acids, or CRISPR ribonucleoproteins into cells. A promising non-viral delivery method.
A synthetic analog of growth hormone-releasing hormone (GHRH) designed for long half-life via albumin binding. Sold as a research chemical; not FDA-approved.
Cell-penetrating peptide. See full entry.
A peptide whose ends are joined to form a ring, or whose side chains are linked to create a macrocycle. Cyclization improves stability, protease resistance, and target affinity. Examples include cyclosporine and oxytocin.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson in Russia. Claimed to activate telomerase and extend lifespan based primarily on Russian rodent studies and small human trials. Not FDA-approved; sold as a research chemical.
A copper-binding tripeptide (Gly-His-Lys + Cu²⁺) discovered by Loren Pickart in 1973. Modulates expression of roughly 4,000 genes and is used in cosmetics for skin repair. Injectable use is a regulatory gray zone.
Glucose-dependent insulinotropic polypeptide — an incretin hormone released from intestinal K-cells. Tirzepatide activates both GIP and GLP-1 receptors for synergistic weight loss effects.
Glucagon-like peptide-1, a natural incretin hormone released from gut L-cells after meals. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists like semaglutide and tirzepatide are now blockbuster obesity and diabetes drugs.
A drug that binds and activates the GLP-1 receptor, mimicking the natural hormone to treat type 2 diabetes and obesity. Examples include semaglutide (Ozempic, Wegovy), liraglutide, and dulaglutide.
A class of gut hormones (primarily GLP-1 and GIP) released after eating that stimulate insulin secretion in a glucose-dependent manner. Incretin-based therapies are the foundation of modern obesity and diabetes drugs.
A selective growth hormone secretagogue peptide that stimulates GH release without affecting cortisol or prolactin. Sold as a research chemical; not FDA-approved.
The covalent attachment of a fatty acid chain to a peptide to enable albumin binding in the bloodstream, dramatically extending half-life. Used in semaglutide and tirzepatide.